Misaki T et al., 1986-12: Japanese clinical series of photodynamic therapy in 46 patients with superficial bladder tumours, using haematoporphyrin derivative and 630 nm laser light. Shows the agent actually used in clinical bladder PDT.
Photodynamic therapy (PDT), using hematoporphyrin derivative (HPD) and the red light (wavelength 630 nm) of an argon-dye laser as the source of excitation energy was performed on 46 patients with superficial bladder tumors. Two methods of laser irradiation, (1) focal PDT using a 400 micron quartz fiber through a cystourethroscope in 22 patients with superficial bladder tumors
Misaki T et al., 1986-12: Japanese clinical series of photodynamic therapy in 46 patients with superficial bladder tumours, using haematoporphyrin derivative and 630 nm laser light. Shows the agent actually used in clinical bladder PDT. Study type: clinical case series (English abstract of a Japanese-language paper). N=46. Country: Japan. Haematoporphyrin derivative (HPD), 630 nm argon-dye laser; two delivery methods (focal fibre in 22, whole-bladder wall in 24). Funding/conflicts: not stated. Comparator: none (single arm). Bearing CONTRADICTS the implication that methylene blue is the clinical bladder PDT agent: the human literature uses HPD, ALA/PpIX and hypericin, not MB. Study type: uncontrolled series.
